Chiome Bioscience Inc
TSE:4583
Intrinsic Value
Chiome Bioscience, Inc. engages in the development and sale of antibody drugs through the Autonomous Diversifying Library (ADLib) system. [ Read More ]
The intrinsic value of one Chiome Bioscience Inc stock under the Base Case scenario is 49.8 JPY. Compared to the current market price of 127 JPY, Chiome Bioscience Inc is Overvalued by 61%.
Valuation Backtest
Chiome Bioscience Inc
Run backtest to discover the historical profit from buying and selling Chiome Bioscience Inc stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Chiome Bioscience Inc
| Current Assets | 1.6B |
| Cash & Short-Term Investments | 1.3B |
| Receivables | 108.2m |
| Other Current Assets | 195.6m |
| Non-Current Assets | 122.1m |
| PP&E | 1.2m |
| Other Non-Current Assets | 120.9m |
| Current Liabilities | 539m |
| Accounts Payable | 37.7m |
| Accrued Liabilities | 32.3m |
| Short-Term Debt | 291m |
| Other Current Liabilities | 178m |
| Non-Current Liabilities | 54.7m |
| Other Non-Current Liabilities | 54.7m |
Earnings Waterfall
Chiome Bioscience Inc
|
Revenue
|
682.5m
JPY
|
|
Cost of Revenue
|
-283.9m
JPY
|
|
Gross Profit
|
398.6m
JPY
|
|
Operating Expenses
|
-1.6B
JPY
|
|
Operating Income
|
-1.2B
JPY
|
|
Other Expenses
|
-14.9m
JPY
|
|
Net Income
|
-1.2B
JPY
|
Free Cash Flow Analysis
Chiome Bioscience Inc
Profitability Score
Profitability Due Diligence
Chiome Bioscience Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Chiome Bioscience Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Chiome Bioscience Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Chiome Bioscience Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Chiome Bioscience Inc
Shareholder Return
Price
Chiome Bioscience Inc
| Average Annual Return | -4.4% |
| Standard Deviation of Annual Returns | 6.27% |
| Max Drawdown | -73% |
| Market Capitalization | 6.7B JPY |
| Shares Outstanding | 55 714 451 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Chiome Bioscience, Inc. engages in the development and sale of antibody drugs through the Autonomous Diversifying Library (ADLib) system. The company is headquartered in Shibuya-Ku, Tokyo-To and currently employs 37 full-time employees. The company went IPO on 2011-12-20. The firm operates in two business segments. The Drug Discovery segment is engaged in the research and development of specific antibodies based on new antigens and mechanisms and licensing to pharmaceutical companies. The Drug Discovery Support segment is engaged in development of lead antibodies for therapeutic drugs in collaborating with pharmaceutical companies in Japan and overseas.
Contact
IPO
Employees
Officers
The intrinsic value of one Chiome Bioscience Inc stock under the Base Case scenario is 49.8 JPY.
Compared to the current market price of 127 JPY, Chiome Bioscience Inc is Overvalued by 61%.
You don't have any saved screeners yet
